Table 1.
Clinical characteristics and outcome in Dutch patients with Fusarium keratitis.
| No. (% or range) | |
|---|---|
| Total no. of cases | 89 |
| Age (years) | 42 (13–85) |
| Gender (women) | 57 (64%) |
| Contact lenses | |
| Soft | 65 (68.5%) |
| Rigid | 4 (4.5%) |
| None | 5 (5.6%) |
| Unknown | 19 (21.4%) |
| Trauma | |
| Yes | 5 (5.6%) |
| No | 84 (94.4%) |
| Visual acuity at diagnosis† | |
| logMAR | 0.8 (−0.10 to 3) |
| Snellen | 0.16 (0.001–1.25) |
| Visual acuity after treatment† | |
| logMAR | 0.2 (0.2–2) |
| Snellen | 0.63 (0.01–0.63) |
| Outcome | |
| Cornea transplantation | 20 (22.5%) |
| Enucleation/evisceration | 7 (7.9%) |
| Healed infiltrate | 62 (69.6%) |
| Corticosteroids use before diagnosis | |
| Yes | 16 (18%) |
| No | 50 (56.2%) |
| Unknown | 23 (25.8%) |
| Antimicrobial treatment at diagnosis | |
| Antibiotics | 39 (43.8%) |
| Antifungals | 1 (1.1%) |
| Combinations* | 25 (28.1%) |
| None | 1 (1.1%) |
| Unknown | 23 (25.8%) |
| Antimicrobial treatment after diagnosis | |
| Amphotericin B (T) | 7 (7.9%) |
| Amphotericin B (T+S) | 1 (1.1%) |
| Voriconazole (T) | 14 (15.7%) |
| Voriconazole (T+S) | 6 (6.7%) |
| Voriconazole (T+S+I) | 1 (1.1%) |
| Natamycin (T) | 1 (1.1%) |
| Chlorhexidine (T) | 5 (5.6%) |
| Antibiotics | 8 (9%) |
| Combinations* | 21 (23.6%) |
| None | 4 (4.5%) |
| Unknown | 21 (23.6%) |
*
Combinations of antibiotics, antifungals, antivirals, and/or antiseptics.
Administration route: T, topical; S, systemic; I, intraocular.
†
Mean (range).